Related Experiment Video
Updated: Feb 23, 2026
Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
Published on: March 9, 2019
Anti-fibrosis effect of nanoparticle-mediated delivery of plasminogen kringle 5
Yi Lu1,2,3, Weizhong Gu1, Yanhong Ren1
1Department of Ophthalmology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China.
Abstract:
Retinal fibrosis, including epiretinal membrane (ERM) and proliferative vitreoretinopathy (PVR), is an ocular disease that can lead to blindness. An efficacious therapy remains an unmet medical challenge. In this study, we intended to explore the inhibitory effects of the nanoparticle-mediated delivery of plasminogen kringle 5 (K5-NPs) on laser-induced ERM and to identify the potential anti-fibrosis targets of K5-NPs. A rat model of laser-induced ERM was used. Control-NPs or K5-NPs were intravitreally injected. ERM formation was observed in vivo. The expression of fibrosis-associated factors including TGF-β, CTGF, and α-SMA was detected by qRT-PCR, Western blot, or immunohistochemistry. Our results showed that K5-NPs effectively inhibit laser-induced ERM formation. The expression of α-SMA, the marker of myofibroblast, apparently decreased in immunostained ERMs in the K5-NPs group. The expression of CTGF, a pro-fibrotic factor, in our ERM rat model was significantly downregulated by K5-NPs. Meanwhile, the expression of TGF-β, the upstream regulator of CTGF, was found to be suppressed by K5-NPs as well. The anti-fibrosis effect of K5-NPs might be achieved by interfering with TGF-β expression, thus abrogating the TGF-β-induced upregulation of CTGF and α-SMA. Our study has an important clinical relevance, demonstrating that K5-NPs might offer an additional efficacious clinical option for treating fibrosis-related diseases.
Insights
Nanoparticle-mediated delivery of plasminogen kringle 5 (K5-NPs) effectively inhibited retinal fibrosis in a rat model. K5-NPs reduced key fibrosis markers, offering a potential new therapy for blinding eye diseases.
Area of Science:
- Ophthalmology
- Regenerative Medicine
- Nanotechnology
Background:
- Retinal fibrosis, including epiretinal membrane (ERM) and proliferative vitreoretinopathy (PVR), is a significant cause of blindness with limited treatment options.
- Developing effective therapies for ocular fibrosis remains a critical unmet medical challenge.
Purpose of the Study:
- To investigate the inhibitory effects of nanoparticle-mediated delivery of plasminogen kringle 5 (K5-NPs) on laser-induced epiretinal membrane (ERM) formation.
- To identify the anti-fibrosis molecular targets of K5-NPs in a preclinical model.
Main Methods:
- A rat model of laser-induced ERM was established for in vivo studies.
- Intravitreal injections of control nanoparticles (NPs) or K5-NPs were administered.
- Expression levels of fibrosis-associated factors, including TGF-β, CTGF, and α-SMA, were analyzed using qRT-PCR, Western blot, and immunohistochemistry.
Main Results:
- K5-NPs demonstrated significant inhibition of laser-induced ERM formation.
- A notable decrease in α-SMA expression, a marker of myofibroblasts, was observed in the K5-NPs group.
- K5-NPs significantly downregulated the pro-fibrotic factor CTGF and its upstream regulator TGF-β.
Conclusions:
- K5-NPs exhibit potent anti-fibrosis effects in a preclinical model of retinal fibrosis.
- The therapeutic mechanism likely involves the suppression of the TGF-β signaling pathway, reducing CTGF and α-SMA upregulation.
- K5-NPs represent a promising therapeutic strategy for treating retinal fibrosis and potentially other fibrosis-related conditions.
